StreetAlpha.app
Home › Stocks › SPRB

Spruce Biosciences, Inc. (SPRB)

$38.00
▼ −6.15%
LAST CLOSE · NOV 20

Spruce Biosciences develops therapies for neurological disorders, led by an enzyme replacement therapy for a rare genetic brain disease. It last closed at $38.00 on Nov 20, down 6.15% on the day. The next earnings report for SPRB is expected around Mon, Mar 8, 2027. For the quarter ended Sep 2026, SPRB reported EPS of -$8.51. Over its last 8 reports the stock moved an average of 4.8% the session after earnings.

AI Auto Pilots
Is SPRB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SPRB.

Key Stats

Last 12 months
Results
Net income
−$67.1M
EPS (diluted)
−$33.29
Valuation
Market cap
$109.2M
2.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$87.7M
At Sep 30
Debt
$19.5M
At Sep 30
Shareholder equity
$66.3M
Shares outstanding
2.9M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $10.1M$10.1MFY2023FY2024: $4.9M$4.9MFY2024FY2025: $0$0FY2025

From SPRB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 8
Estimated date · Time not announced
Reported EPS
-$8.51
Quarter ended Sep 2026
Year ago EPS
-$14.58
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$42.72Dec '24Mar 2025: -$23.95Mar '25Jun 2025: -$3.50Jun '25Sep 2025: -$14.58Sep '25Dec 2025: -$9.58Dec '25Mar 2026: -$8.94Mar '26Jun 2026: -$6.68Jun '26Sep 2026: -$8.51Sep '26Latest -$8.51
Revenue by quarter
Dec 2024: $697,000Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Latest $0
How SPRB moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 9, 2026Time not announced+6.0%
Aug 12, 2026Time not announced+1.4%
May 13, 2026Time not announced+1.6%
Mar 9, 2026Time not announced+11.2%
Jan 8, 2026Time not announced−5.6%
Nov 10, 2025After the close−2.5%
Apr 1, 2025After the close+9.2%
Nov 12, 2024Time not announced−1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SPRBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SPRB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SPRB

Technical Analysis

SPRB · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 16% below its 20 day and 20% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $37.01, and the nearest resistance the Pivot at $38.99.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.9%/day
Key levels
$115.0052 week high+202.6%
$53.13200 day average+39.8%
$48.05100 day average+26.4%
$45.6550 day average+20.1%
$45.51Swing high (Jul 27)+19.8%
$44.1820 day average+16.3%
$39.97Pivot R1+5.2%
$38.99Pivot+2.6%
$38.0052 week low+0.0%
$38.00Last close
$37.01Pivot S1−2.6%
Indicators
RSI (14)36.76Weak, oversold below 30Neutral
MACD-1.47Below its signal lineBearish
Stochastic5.1Near the bottom of its rangeOversold
ADX (14)13.3No clear trend
Williams %R-100.0Oversold below −80, overbought above −20Oversold
CCI (20)-183.4Oversold below −100, overbought above 100Oversold
Rate of change−18.4%Change over 10 sessionsBearish
ATR (14)$3.40Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRB

What happened before

See how SPRB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SPRB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SPRB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SPRBHow many large options trades hit SPRB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SPRB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲36 buying vs 23 selling
  • ▼Held by funds -2.2 pts
  • ▲Funds holding +7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7164+10.9%
In funds' top 10110.0%
Held by funds72.6%74.8%−2.2 pts
New / increased12 / 2436 / 16−30.8%
Reduced / sold out17 / 63 / 4+228.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SPRB Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 6, 2025Parkman Healthcare Partners LLC10% ownerBuy256$17.91$5K
Oct 6, 2025Parkman Healthcare Partners LLC10% ownerSale257$19.15$5K
Oct 6, 2025Parkman Healthcare Partners LLC10% ownerBuy256$17.91$5K
Oct 6, 2025Parkman Healthcare Partners LLC10% ownerSale257$19.15$5K
Every insider buy and sale for SPRB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SPRB insider trades →

From SEC Form 4 filings by SPRB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRB is in one of them and how their past SPRB trades turned out.

SPRB in the AI portfolios
Loading…

SPRB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRB in an article yet. Here's the latest on the wider market.

SPRB in the news

About Spruce Biosciences

Spruce Biosciences is a biopharmaceutical company that develops therapies for neurological disorders. Its lead product candidate, TA-ERT, is an enzyme replacement therapy under development for MPS IIIB, a rare genetic disease that causes progressive brain damage and has no approved treatments. The therapy is designed to be delivered directly into the central nervous system, and its intended customers are patients with the disease and the clinicians who treat them. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA